NCT04610372Recruiting
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
Moderate Versus Ultra Hypofractionation or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will maintain favorable toxicity profiles and quality of life while achieving comparable or better efficacy, thereby providing a convenient and cost-effective alternative to moderately hypofractionated EBRT.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 168 (estimated)
- First submitted
- 14 Oct 2020
- Start date
- 12 Jul 2021
- Primary completion date
- 30 Jun 2030
- Lead sponsor
- British Columbia Cancer Agency
- Diseases
- Prostate cancer
- NCT number
- NCT04610372
What you commit to
- Study type: Interventional
- Planned participants: 168
- From 12 Jul 2021 to the primary completion date, 30 Jun 2030
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contraindications to EBRT such as active inflammatory bowel disease or previous pelvic radiation
- For Brachytherapy Arms =: Any prior Transurethral resection of prostate
Other
- High metastatic burden defined as 5 or more bone metastases or visceral metastases
Who the study is looking for
- Signed study specific informed consent
- European Cooperative Oncology Group performance status 0 to 2
- Histologically confirmed adenocarcinoma of the prostate
- Any Tumor stage, any T, any N, M1
- No prior therapy for prostate cancer apart from androgen deprivation
- Planned for long-term androgen deprivation therapy (greater than 9 months in duration)
- Patient is able and willing to complete the quality of life questionnaires, and other assessments that are a part of this study
- For brachytherapy arms, patient must be technically suitable for brachytherapy according to investigator, in terms of bladder function and prostate size.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| British Columbia Cancer Agency Center for the Southern Interior Coordinator of this site? Confirm its status | Kelowna | Canada | Recruiting |
| Fraser Valley Cancer Center Coordinator of this site? Confirm its status | Surrey | Canada | Not yet recruiting |
| Vancouver Cancer Center Coordinator of this site? Confirm its status | Vancouver | Canada | Recruiting |
| Vancouver Island Cancer Center Coordinator of this site? Confirm its status | Victoria | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.